Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02938611

Feasibility of Estimating the Prevalence and Management of Stage 4 CKD the Gard, France

The main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France from data obtained via laboratory databases. To verifiy if the demand for care thus authenticated by laboratory tests is adapted to nephrology care delivery, as recommended by the French High Authority of Health (HAS), laboratory data will be compared with those of patients seen by nephrologists in the department.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Renal Insufficiency, Chronic Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Urogenital Diseases Urologic Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

AIDER - Unité de Dialyse d'Alès, Alès, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • chronic kidney disease (stage >= 4)

Exclusion criteria

-

Treatment and study plan

Primary outcomes

  1. The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (raw number)

    Time frame: from baseline (day 0) to 12 months

  2. The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (%)

    Time frame: from baseline (day 0) to 12 months

Secondary outcomes

  1. The percentage of patients with CKD stage >= 4 correctly reported by participating nephrologists

    Time frame: from baseline (day 0) to 12 months

  2. For each nephrologist participating in the study, the % of patients with stage >=4 chronic kidney disease who are correctly declared

    Time frame: from baseline (day 0) to 12 months

  3. The % of patients with chronic kidney disease stage > = 4 in the Gard according to laboratory data and who are not seen by a nephrologist

    Time frame: from baseline (day 0) to 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Olivier Moranne, MD, PhD

CONTACT

[email protected]

+33.(0)4.66.68.31.49

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Registry information

Official study title

Feasibility Study on Estimating the Prevalence and Management of Stage 4 Chronic Kidney Disease in Adults Via Laboratories and Nephrologists in the Gard, France

Acronym: MRC-Gard

Important dates

Study start
2019
Primary completion
2025
Study completion
2025
First posted
Oct 19, 2016
Registry last updated
Mar 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.